Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
Stereotaxis logo — Pioneering Endovascular Robotics

Stereotaxis

Pioneering Endovascular Robotics

Founded 1990 United States United States 200 employees Post-IPO Equity Total: $105.00M Biotechnology, Health Care +1

General Information

Company Name Stereotaxis
Founded Year 1990
Location United States United States
Founders / Decision Makers
Team member
Employees 200
Industries Biotechnology, Health Care, Medical Devices
Funding Stage Post-IPO Equity
Social

BounceWatch is an independent company data service, not affiliated with Stereotaxis. To contact Stereotaxis, visit stereotaxis.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

About Stereotaxis

Stereotaxis is a biotechnology and health care startup based in the United States, founded in 1990. The company's slogan, "Pioneering Endovascular Robotics," encapsulates its focus on revolutionizing the treatment of arrhythmias and conducting endovascular procedures through cutting-edge robotic technologies. Stereotaxis garnered attention with a substantial $25.00M Post-IPO Equity investment on 08 August 2019, with backing from notable investors including the Redmile Group, Parkman Healthcare Partners LLC, and Opaleye Management. Stereotaxis has positioned itself as a global leader in the realm of endovascular robotics, signaling vast growth potential in an industry ripe for innovation. With a compelling focus on enhancing medical procedures using robotics, the company is well-positioned to capitalize on the increasing demand for advanced medical technologies. The recent significant investment not only affirms the market's confidence in the company but also provides Stereotaxis with the necessary resources to drive further innovation and expansion in the field of endovascular robotics.

Taxonomy: Medical Robotics, Endovascular Robotics, Robotic Cardiology, Arrhythmia Treatment, Coronary Disease Treatment, Interventional Lab Technology, Remote Magnetic Navigation System, Lab Optimization, Patient Information Management, Robotic Mechanical Navigation System, Medical Technology, Surgical Robotics, Healthcare Innovation, Medical Device, Interventional Surgery

Funding Rounds & Investors (7)

View All
Funding Stage Amount Investors Lead Investors Date
Post IPO Equity $25.00M 3
Redmile Group Parkman Healthcare Partners LLC
Redmile Group, Parkman Healthcare Partners LLC +1
08 Aug 2019
Post IPO Equity $10.00M -
06 Mar 2018
Post IPO Equity $24.00M -
27 Sep 2016
Post IPO Equity $10.00M -
29 May 2012
Venture Round $16.00M -
01 Jan 2004
Venture Round $20.00M 6
Advantage Capital Partners Ascension Ventures
Advantage Capital Partners, Ascension Ventures +4
10 Jan 2003
Venture Round Undisclosed 1
Advantage Capital Partners
Advantage Capital Partners
31 Jul 1998

Stereotaxis Alternatives & Competitors

View All Alternatives
Stereotaxis vs
Roxwood Medical
Roxwood Medical

Innovative solutions for advanced cardiovascular specialty catheters in Interventional Cardiology, E...

Venture round
Health Care, Medical Devices
Stereotaxis vs
Centerline Biomedical
Centerline Biomedical United States

A New Way to Envision Interventional Navigation

Series B
45 employees
Biotechnology, Health Care
Compare Stereotaxis vs Centerline Biomedical
Stereotaxis vs
AcuSurgical
AcuSurgical France

Creating the new standard of care in retinal surgery

Series A
40 employees
Health Care, Medical Devices
Also compare with: Stereotaxis vs Interventional Systems Interventional Systems View all alternatives

FAQ About Stereotaxis

Pioneering Endovascular Robotics
Stereotaxis was founded in 1990.
Stereotaxis is headquartered in United States.
Stereotaxis operates in Biotechnology, Health Care and Medical Devices. Its work centres on Medical Robotics, Endovascular Robotics, Robotic Cardiology and Arrhythmia Treatment.
Stereotaxis has approximately 200 employees.
Stereotaxis has completed 7 funding rounds, raising a total of $105.00M. The latest funding stage is Post-IPO Equity.
Top alternatives and competitors to Stereotaxis include Roxwood Medical, Centerline Biomedical, AcuSurgical, Point Robotics, 苏州润迈德医疗科技有限公司. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Stereotaxis and Roxwood Medical are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Stereotaxis, https://bouncewatch.com/company/stereotaxis, updated 30 December 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes